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Abstract
Background: Data is lacking in the literature regarding the prognostic impact of left ventricular-end diastolic pressure 
(LVEDP) across acute coronary syndromes (ACS).
Objective: To assess LVEDP and its prognostic implications in ACS patients.
Methods: Prospective, longitudinal and continuous study of 1,329 ACS patients from a single center between 2004 and 
2006. Diastolic function was determined by LVEDP. Population was divided in two groups: A - LVEDP < 26.5 mmHg (n 
= 449); group B - LVEDP ≥ 26.5 mmHg (n = 226).
Results: There were no significant differences between groups with respect to risk factors for cardiovascular disease, 
medical history and medical therapy during admission. In group A, patients with non-ST elevation ACS were more 
frequent, as well as normal coronary angiograms. In-hospital mortality was similar between groups, but one-year 
survival was higher in group A patients (96.9 vs 91.2%, log rank p = 0.002). On a multivariate Cox regression model, 
a LVEDP ≥ 26.5 mmHg (HR 2.45, 95%CI 1.05 - 5.74) remained an independent predictor for one-year mortality, when 
adjusted for age, LV systolic ejection fraction, ST elevation ACS, peak troponin, admission glycemia, and diuretics at 24 
hours. Also, a LVEDP ≥ 26.5 mmHg was an independent predictor for a future readmission due to congestive HF (HR 
6.65 95%CI 1.74 – 25.5).
Conclusion: In our selected population, LVEDP had a significant prognostic influence. (Arq Bras Cardiol 2011; 97(2) : 100-110)
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Introduction
After 10 to 20 seconds of coronary artery occlusion, 
relaxation time starts to shorten with a simultaneous rise in 
left ventricular end-diastolic pressure (LVEDP). Wall motion 
abnormalities occur between 15 and 30 seconds after culprit 
occlusion, and are followed by a drop in ejection fraction. 
After this cascade, ischemic symptoms and electrical signs 
of ischemia may ensue. Nevertheless, this presentation is 
highly variable, and is dependent on collateral flow, collateral 
perfusion and ischemic preconditioning1. 
According to the 1998 European Society Cardiology 
working group report about how to diagnose diastolic 
HF, three obligatory conditions have to be simultaneously 
satisfied: 1 - the presence of signs of congestive heart failure 
(HF); 2 - presence of normal or only mildly abnormal left 
ventricular (LV) systolic function; 3 - evidence of abnormal LV 
relaxation, filling, diastolic distensibility or diastolic stiffness2. 
The 2007 revised document challenged the third topic, 
recognizing the difficulties in the assessment of diastolic LV 
function, and based on recent data3, the measurement of 
diastolic LV function was not required to attain the diagnosis 
of diastolic HF, also named HF with normal ejection fraction. 
Nevertheless the authors remarked that invasively acquired 
evidence of diastolic LV dysfunction remains definite 
evidence of HF with preserved systolic function4.
Both documents stated that the presence of a LVEDP 
> 16 mmHg in the presence of a non-dilated left ventricle 
is synonymous of LV diastolic distensibility reduction and 
therefore, a marker of LV diastolic dysfunction5. 
Previous authors demonstrated that an elevated pulmonary 
capillary wedge pressure (PCWP) and a low cardiac index were 
independent predictors of outcome in the context of acute 
myocardial infarction (AMI)6-8. Most of the present data in the 
literature on ACS patients and diastolic function is related to 
the noninvasive echocardiographic assessment of LV diastolic 
function. As reported by Oh et al9 a restrictive filling pattern 
after an AMI was associated with the occurrence of in-hospital 
HF. Other echocardiographic indexes were also considered of 
prognostic value, such as the deceleration time (DT) < 140 
ms10-12, and also the E/E’ ratio greater than 15, as reported 
by Hillis et al13. This last group observed than in 250 patients 
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with AMI the E/E’ ratio had a prognostic role with respect to 
all-cause mortality with an incremental value over age and 
left ventricular ejection fraction. Nevertheless, there was some 
conflicting data in the literature regarding diastolic function 
as a maker of prognosis, such as the study ATTenuation by 
Adenosine of Cardiac Complications (ATTACC), a randomized 
controlled trial of the addictive value of adenosine over 
fibrinolysis in ST elevation AMI, which failed to demonstrate 
the independent prognostic importance of restrictive filling 
defined by either a DT < 140 ms, or E/A ratio > 214. 
Due to the lack of prognostic data related to invasively 
determined left ventricular filling patterns in current ACS 
patients, namely with respect to LVEDP, we hypothesized that 
LVEDP would predict an adverse outcome after an ACS. To test 
this hypothesis, we evaluated the prognostic value of LVEDP 
in a non-selected single center ACS population admitted for 
an invasive strategy during the acute phase.
Methods
Study population
The present was a continuous, observational, and 
prospective study of 1,459 consecutive admissions due to 
ACS, between May 2004 and December 2006, in a single 
center coronary care unit. We excluded 130 records as they 
were readmissions. The final population consisted of 1,329 
patients. Of these, we selected the ones admitted for an 
invasive strategy - 786 patients.
AMI was defined according to the Universal Definition of 
myocardial infarction, as a positive cardiac biomarker (namely 
troponin I) with symptoms of ischemia or ECG changes 
indicative of new ischemia (ST and T wave and new bundle 
branch block)15. 
Regarding ECG data, ST elevation AMI was defined by a new 
onset of ST elevation > 2 mm in the precordial leads for men 
and 1.5 mm for women and greater than 1 mm in other leads. 
Non-ST elevation AMI, in addition to the previous laboratorial 
and clinical criteria, could be associated or not with ECG 
ischemic changes (namely ST depression or T wave inversion)15. 
Unstable angina was defined either by new onset angina 
(at least class III CCS), progressive angina, or angina at rest, 
with or without ECG ischemic changes, and a negative cardiac 
biomarker assay16. 
LV systolic function was assessed by echocardiography, 
according to the Simpson method. The examination 
considered for this study was performed within 24 hours after 
the invasive assessment.
LVEDP was determined in the catheterization laboratory 
using a calibrated fluid filled system before left ventriculography. 
LVEDP was measured at the Z-point, which was identified 
on the left ventricular pressure trace as the point at which 
the slope of the ventricular pressure upstroke changes, 
approximately 50 ms after the ECG Q wave, and generally 
coinciding with the ECG R wave17. The decision to determine 
LVEDP was left at the discretion of the hemodynamicist. All 
the patients were referred to the invasive procedure primarily 
to diagnose coronary artery disease, and not exclusively for 
an invasive assessment of LV hemodynamics.
Cardiac biomarkers namely, troponin I and MBCK were 
assessed daily, and the peak values during hospital stay were 
used in our analysis. 
Population was divided in two groups based on the LVEDP. 
Group A included 449 patients that had LVEDP < 26.5 mmHg. 
Group B patients had LVEDP ≥ 26.5 mmHg and comprised 
226 individuals. LVEDP was not determined in 111 patients.
This investigation conformed to the principles outlined 
in the Declaration of Helsinki. The local ethics committee 
approved the research protocol and informed consent has 
been obtained from all subjects.
Baseline data and patient follow-up
We analyzed standardized records during admission that 
included demographic, clinical, electrical, echocardiographic 
and laboratorial data. Medical therapy, catheterization data, intra-
hospital course and discharge medication were also recorded.
We performed a median clinical follow up of 19 months 
after hospital discharge. The information was collected 
by phone call, from hospital records or at the outpatient 
clinic. The primary endpoint was all-cause mortality one 
year after discharge. Other results were also analyzed, such 
as the combined result of cardiovascular death, non-fatal 
infarction, re-admission for unstable angina, and unscheduled 
percutaneous coronary intervention - MACE, and re-admission 
for congestive HF one year after the culprit ACS admission. 
Statistical analysis
The Kolmogorov-Smirnov test was used to assess if 
continuous variables were normally or non-normally 
distributed. Continuous data were presented as mean and 
standard deviation and compared with the Student t-test. 
Categorical variables were reported as frequencies and 
percentages, and the χ2 test or the exact Fisher tests were 
used when appropriate.
The cumulative survival curves were constructed with the 
use of the Kaplan-Meier method and groups were compared 
with the Log rank test. The observational period started at 
hospital discharge and lasted for one year.
A multivariate Cox regression analysis was performed for 
the primary endpoint, and also for HF readmission one year 
after the ACS. Variables that were significant at the bivariate 
level (p < 0.05) or that had a clinical relevance, were included 
in the models.
With the exception of the Kolmogorov-Smirnov all 
statistical tests were two-tailed and a p value less than 0.05 
was deemed significant. The analysis was performed with the 
SPSS 15 (Statistical Package for Social Sciences) from SPSS Inc, 
Chicago, IL.
Results
LVEDP was available for 675 patients. The mean value for 
the population was 23.2 mmHg, with a maximum value of 
52.0 mmHg, and a minimum of 2.3 mmHg.
The cutoff value of 26.5 mmHg had the highest sensitivity 
(58%) and specificity (61%) - area under ROC 0.60, for the 
primary endpoint selected (all-cause mortality).
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The study cohort consisted of 499 male and 176 female 
individuals with a mean age of 63.5 years. The baseline 
demographic, clinical characteristics and in-hospital 
management of both groups of patients are presented in 
Tables 1 to 4. 
A higher LVEDP was associated with STEMI, higher peak 
values of cardiac biomarkers, a lower left ventricular ejection 
fraction (LVEF), and a more dilated left ventricle. There was a 
negative significant correlation between LVEDP and LVEF (r: 
-0.324, p value < 0.01). 
Patients with a lower LVEDP had a lower likelihood of in-
hospital HF, were less often prescribed a diuretic at 24 hours 
(17.4 vs 28.3%, p = 0.001), and had more frequently a normal 
coronary angiogram.
There were no other significant differences with respect to 
intrahospital and discharge medical therapy. The in-hospital 
mortality was similar for both groups (2.4 vs 4.9%, p = 0.095).
Outcome
With respect to follow up, data was available for 618 (lost-
to-follow-up rate of 5.4%) of the discharged patients.
A higher LVEDP was associated with a lower survival status 
at one, six and twelve months after discharge - Table 5. The 
cumulative one year survival rate was significantly lower for 
group B patients (96.9 vs 91.2% log rank p = 0.002) - Figure 
1. This difference remained significant for the subgroup with 
preserved systolic function (LVEF ≥ 40%), but the stratification 
proposed for LVEDP as a survival marker was not significant 
for the depressed LV function (LVEF < 40%). The p value 
for interaction between these last three variables was not 
significant (0.59).
In the univariate analysis, a LVEDP ≥ 26.5 mmHg was 
significantly associated with a higher mortality one year 
after discharge - Table 6, as were age, LVEF, STEMI, diuretics 
at 24 hours, glycemia at admission, and the peak value of 
Table 1 - Baseline characteristics
All patients A - LVEDP < 26.5 B - LVEDP ≥ 26.5 p
Number of patients 675 449 226
Male gender (%) 499/675 (73.9) 337/449(75.1) 162/226 (71.7) 0.35
Age (mean, SD) 63.5 ± 12.4 63.3 ± 11.8 63.8 ± 13.4 0.61
Admission diagnosis (%)
STEMI 281/654 (43.0) 164/439 (37.3) 117/215 (54.4) <0.01
NSTEMI 234/654 (35.8) 171/439 (39.0) 63/215 (29.3) 0.01
UA 123/654 (18.8) 94/439 (21.4) 29/215 (13.5) 0.02
Undetermined pattern 16/654 (2.4) 10/439 (2.3) 6/215 (2.8) 0.69
Risk factors cardiovascular disease (%)
Diabetes 171/671 (25.3) 108/446 (24.2) 63/225 (28.0) 0.29
Dyslipidemia 439/628 (65.0) 283/416 (68.0) 156/212 (73.6) 0.15 
Hypertension 440/631 (65.2) 284/418 (67.9) 156/213 (73.2) 0.17 
Current smoking habits 153/675 (22.7) 101/449 (22.5) 52/226 (23.0) 0.88 
Cardiovascular history (%)
Previous myocardial infarction 89/616 (13.2) 57/409 (13.9) 32/207 (15.5) 0.61
Previous PCI 67/661 (9.9) 44/439 (10.0) 23/222 (10.4) 0.89
Previous HF 2/310 (0.3) 1/235 (0.4) 1/75 (1.3) 0.39
Previous stroke 36/671 (5.3) 27/446 (6.1) 9/225 (4.0) 0.27
Previous medication (%)
Aspirin 150/401 (37.4) 106/275 (38.5) 44/126 (34.9) 0.49
Other anti-platelet 51/401 (12.7) 35/275 (12.7) 16/126 (12.7) 0.99
Beta-blocker 86/401 (21.4) 62/275 (22.5) 24/126 (19.0) 0.43
ACE inhibitors 148/401 (36.9) 104/275 (37.8) 44/126 (34.9) 0.58
Statins 133/401 (33.2) 91/275 (33.1) 42/126 (33.3) 0.96
Diuretics 77/401 (19.2) 56/275 (20.4) 21/126 (16.7) 0.38
Nitrates 72/401 (18.0) 52/275 (18.9) 20/126 (15.9) 0.46
STEMI - ST-elevation acute myocardial infarction; NSTEMI - non-ST elevation acute myocardial infarction; UA - unstable angina; PCI - percutaneous coronary intervention; 
HF - heart failure; ACE - angiotensin-converting enzyme; LVEDP - left ventricular-end diastolic pressure.
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Table 2 - Hemodynamic, electrical and laboratory data
All patients A - LVEDP < 26.5 B - LVEDP ≥ 26.5 p
Hemodynamic data on admission 
Heart rate, bpm (mean, SD) 76.5 ± 15.3 75.2 ± 15.3 78.8 ± 15.4 0.05 
Systolic blood pressure, mmHg (mean, SD) 135.0 ± 24.3 136.3 ± 23.2 134.8 ± 26.8 0.46 
Diastolic blood pressure, mmHg (mean, SD) 73.9 ± 14.2 73.4 ± 13.7 74.3 ± 15.3 0.48 
TIMI risk score ≤ 2 (%) 342/675 (50.7) 236/449 (52.6) 106/226 (46.9) 0.17
TIMI risk score 3 - 4 (%) 276/675 (40.9) 177/449 (39.4) 99/226 (43.8) 0.27
TIMI risk score ≥ 5 (%) 57/675 (8.4) 36/449 (8.0) 21/226 (9.3) 0.57
Body mass index (kg/m2) 27.7 ± 4.8 27.4 ± 4.6 28.3 ± 5.3 0.03 
Electrical data on admission (%) 
Sinus Rhythm 613/671 (91.4) 409/446 (91.7) 204/225 (90.7) 0.65
AF 36/671 (5.4) 23/446 (5.2) 13/225 (5.8) 0.74
ST depression 47/671 (7.0) 33/446 (7.4) 14/225 (6.2) 0.57
T wave inversion 96/671 (14.3) 69/446 (15.5) 27/225 (12.0) 0.23
Laboratory (mean, SD)
Peak Troponin I, U/l 44.5 ± 63.0 33.0 ± 58.2 53.9 ± 69.0 <0.01 
Peak MBCK mass, U/l 125.4 ± 177.7 96.9 ± 134.8 171.0 ± 233.2 <0.01 
Total cholesterol, mg/dl 194.7 ± 49.6 192.7 ± 48.4 199.0 ± 53.2 0.20 
LDL cholesterol, mg/dl 131.2 ± 37.0 130.4 ± 36.1 133.9 ± 39.7 0.34 
HDL cholesterol, mg/dl 43.3 ± 10.3 42.4 ± 10.0 44.5 ± 10.5 0.04
Glomerular filtration rate ml/min 71.5 ± 21.5 72.4 ± 20.7 69.4 ± 23.2 0.12 
Admission glycemia, mg/dl 149.4± 63.9 155.5 ± 68.4 144.7 ± 59.0 0.06 
Admission hemoglobin, g/dl 14.2 ± 1.6 14.2 ± 1.7 14.0 ± 1.6 0.20 
Minimum hemoglobin, g/dl 12.4 ± 1.7 12.4 ± 1.7 12.1 ± 1.7 0.06 
AF - atrial fibrillation; LVEDP - left ventricular-end diastolic pressure.
Table 3 - In-hospital management
In the first 24 hours Medication at discharge
A - LVEDP < 26.5 B - LVEDP ≥ 26.5 p A - LVEDP < 26.5 B - LVEDP ≥ 26.5 p
ASA (%) 436/449 (97.1) 219/226 (96.9) 0.88 388/438 (88.6) 197/215 (87.2) 0.45
Clopidogrel (%) 332/449 (73.9) 179/226 (79.2) 0.13 268/438 (61.2) 138/215 (64.2) 0.46
Beta-Blockers (%) 381/449 (84.9) 184/226 (81.4) 0.25 349/438 (79.7) 169/215 (78.6) 0.75
ACE inhibitors (%) 406/449 (90.4) 206/226 (91.2) 0.76 389/438 (88.8) 187/215 (87.0) 0.49
Statins (%) 444/449 (98.9) 221/226 (97.8) 0.27 417/438 (95.2) 206/215 (95.8) 0.73
Gp IIb/IIIa inhibitors (%) 241/449 (53.7) 136/226 (60.2) 0.11
LMWH 444/449 (98.9) 221/226 (97.8) 0.27
Diuretic (%) 78/449 (17.4) 64/226 (28.3) 0.01
Nitrates (%) 165/449 (36.7) 83/226 (36.7) 0.99
ASA - acetyl salicylic acid; LMWH - low molecular weight heparin; Gp - glycoprotein; LVEDP - left ventricular-end diastolic pressure.
troponin I. In a composite model that included the previous 
seven variables, LVEDP as a continuous variable was not 
an independent predictor of outcome (HR 1.03, 95% CI 
0.98 - 1.08, p = 0.17) - Table 6. There were no interactions 
between LVEDP and LVEF regarding this endpoint, as in a Cox 
regression model that included only those two variables, they 
both remained significant (data not shown).
The cumulative freedom from congestive HF in the year 
after the index hospitalization was significantly higher for the 
lower LVEDP patients (98.1 vs 93.2%, log rank p = 0.004) - 
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Table 4 - Echo and cath lab data
A - LVEDP < 26.5 B - LVEDP ≥ 26.5 p
Echocardiographic data
Left atrium, mm º 41.4 ± 6.6 41.4 ± 6.5 0.97
LV end systolic diameter, mm º 38.9 ± 6.9 41.7 ± 7.8 <0.01
LV end diastolic diameter, mm º 56.2 ± 6.6 58.4 ± 6.6 <0.01
LVEF, % º 54.6 ± 9.05 48.8 ± 11.2 <0.01 
LVEF < 40% * 58/447 (13.0) 64/226 (28.3) <0.01
LV shortening fraction, % º 31.5 ± 5.5 29.8 ± 6.2 0.01
LV motility wall abnormality * 233/332 (70.2) 146/175 (83.4) 0.01
Mitral regurgitation * 202/359 (56.3) 115/191 (60.2) 0.73
Pulmonary artery systolic pressure, mmHg º 32.4 ± 10.4 31.9 ± 11.0 0.81
Cath lab data
Time to balloon (primary angioplasty), hours 2.0 ± 1.9 1.5 ± 1.5 0.06
Coronary angiogram ≤ 48 hours *+ 79/224 (35.3) 30/70 (42.9) 0.25
Coronary angiogram > 48 hours * + 145/224 (64.7) 40/70 (57.1) 0.25
Normal coronary angiogram * 68/418 (16.3) 19/211 (9.0) 0.01
1 vessel coronary disease * 172/418 (41.1) 91/211 (43.1) 0.64
2 vessel coronary disease * 96/418 (23.0) 52/211 (24.6) 0.64
3 vessel coronary disease * 77/418 (18.4) 49/211 (23.2) 0.16
Fully revascularized* 172/350 (49.1) 94/192 (49.0) 0.96
Partially revascularized* 89/350 (26.0) 50/192 (26.0) 0.88
Not revascularized* 89/350 (25.4) 48/192 (25.0) 0.91
Stent* 258/418 (61.7) 133/211 (63.0) 0.75
Drug eluting stents* 181/258 (70.2) 91/132 (68.9) 0.81
Surgical revascularization* 16/418 (3.8) 6/211 (2.8) 0.53
º - mean ± SD; * - %; + for non-ST elevation ACS; LVEF - left ventricular ejection fraction, LVEDP - left ventricular-end diastolic pressure.
Table 5 - Outcomes in the hospital and 1 year after discharge
A - LVEDP < 26.5 B - LVEDP ≥ 26.5 OR (95% CI) p
Length of stay (days) 5.2 ± 2.5 5.9 ± 3.7 <0.01
In-hospital mortality (%) 11/449 (2.4) 11/226 (4.9) 1.99 (0.88 – 4.51) 0.01
In-hospital diagnosis of heart failure (%) 128/446 (28.7) 84/225 (37.3) 1.48 (1.05 – 2.08) 0.02
Overall mortality 30 days (%) 1/414 (0.2) 4/204 (2.0) 8.12 (0.91 – 72.2) 0.03
Overall mortality 6 months (%) 9/414 (2.2) 14/204 (6.9) 3.16 (1.39 – 7.17) <0.01
Overall mortality 1 year (%) 13/414 (3.1) 18/204 (8.8) 2.81 (1.41 – 5.62) 0.01
Cumulative mortality 30 days (%) 12/449 (2.7) 15/226 (6.6) 2.48 (1.18 – 5.22) <0.01
Cumulative mortality 6 months (%) 20/449 (4.5) 25/226 (11.1) 2.48 (1.41 – 4.37) <0.01
Cumulative mortality 1 year (%) 24/449 (5.3) 29/226 (12.8) 2.40 (1.43 – 4.03) <0.01
MACE 1 year (%) 46/414 (11.1) 33/204 (16.2) 1.45 (0.96 – 2.19) 0.08
HF 1 year (%) 8/414 (1.9) 14/204 (6.9) 3.59 (1.51 – 8.33) 0.01
MACE - major adverse cardiovascular endpoint; HF - heart failure; LVEDP - left ventricular-end diastolic pressure.
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Figure 2. The proposed stratification of the LVEDP also had a 
significant impact in the subpopulation with LVEF ≥ 40%, but 
not in the ones with LVEF < than 40%. The p value for the 
interaction of LVEDP, LVEF, and HF in the follow-up was not 
significant (0.37). LVEDP as a continuous variable remained 
an independent predictor of HF readmission, in a composite 
model that included LVEDP (as a continuous variable), age, 
LVEF, peak troponin I, STEMI, TIMI risk score, diuretics at 24 
hours and atrial fibrillation - Table 7.
Discussion
Our data confirmed LVEDP as a risk stratification variable 
during an ACS. As a continuous variable and after adjustment, 
Figures 1. e 2 - Outcomes with respect to overall survival and HF readmission one year after the ACS.
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Table 6 - Univariate predictors of all-cause mortality one year after the ACS
Survivors Deceased OR (95% CI) p
Number 587 31
Female gender* 150/587 (25.6) 7/31 (22.6) 0.85 (0.36 – 2.01) 0.71
STEMI* 238/570 (41.8) 19/29 (65.5) 2.65 (1.21 – 5.80) 0.01
Diabetes* 142/587 (24.2) 11/31 (35.5) 1.72 (0.81 – 3.68) 0.16
Hypertension* 386/553 (69.8) 22/27 (81.5) 1.90 (0.71 – 5.11) 0.19
Atrial fibrillation * 29/587 (4.9) 1/31 (3.2) 0.64 (0.08 – 4.87) 0.67
ECG ST depression * 41/587 (7.0) 1/31 (3.2) 0.44 (0.06 – 3.34) 0.42
Normal coronary angiogram* 85/587 (14.5) 1/31 (3.2) 0.20 (0.03 – 1.46) 0.08
Three vessel disease* 114/587 (19.4) 10/31 (32.3) 1.98 (0.91 – 4.31) 0.08
Complete percutaneous revascularization* 248/502 (49.4) 11/30 (36.7) 0.59 (0.28 – 1.27) 0.18
Diuretics 24 hours * 102/587 (17.4) 15/31 (48.4) 4.46 (2.13 – 9.31) <0.01
Peak troponin I higher (U/l) º 33.7 ± 51.4 92.9 ± 102.0 <0.01
Glycemia admission (mg/dl) º 144.1 ± 60.3 184.9 ± 66.0 <0.01
Age (years) º 62.9 ± 12.1 71.3 ± 109 <0.01
LVEDP (mmHg) * 23.0 ± 8.1 27.3 ± 11.7 <0.01
LVEF (%) º 53.2 ± 9.9 45.1 ± 11.4 <0.01
BMI (kg/m2) º 27.7 ± 4.8 27.0 ± 3.5 0.41
Glomerular filtration rate (ml/min) º 72.4 ± 20.4 71.6 ± 26.0 0.82
º mean ± SD; * %
Multivariate Cox regression analysis for overall mortality one year after the ACS
Variables HR p value 95% C I
Peak troponin I 1.01 <0.01 1.00 – 1.01
Age 1.05 0.02 1.01 – 1.09
Glycemia admission 1.01 0.02 1.00 – 1.01
Diuretics 24 hours 2.35 0.048 1.01 – 5.48
LVEDP 1.03 0.17 0.98 – 1.08
STEMI 1.13 0.80 0.44 – 2.90
LVEF 0.99 0.45 0.96 – 1.02
Number of events - 27; Population - 490 patients; Chi square - 47.3; p < 0.01. LVEF - left ventricular ejection fraction; LVEDP - left ventricular end diastolic pressure; ECG 
- Eletrocardiogram; BMI - body mass index.
LVEDP had a prognostic impact regarding HF readmission after 
an ACS - for each 1 mmHg increase, the relative risk increased 
1.10 times (1.04 to 1.16). On the contrary, LVEDP was not an 
independent predictor with respect to in-hospital mortality, 
one-year mortality and one-year ischemic complications (MACE 
rate). The cutoff of 16 mmHg used to identify LV diastolic 
dysfunction4, was not an univariate predictor of follow-up 
mortality. It was associated with a higher rate of readmission for 
HF (data not shown), but with lower sensitivity and specificity.
Prognosis
As previously reported, a higher PCWP - a maker of LV 
diastolic distensibility, in the context of acute MI was associated 
with larger infarcts18 and with a worse LV systolic function19. 
In our population, a higher LVEDP was more frequently 
related with STEMI, and with higher peak values of troponin 
I. That was in agreement with the work of Bronzear et al20, 
as ischemic myocardium was associated with higher LV filling 
pressures and reduced left ventricular distensibility during 
pace-induced ischemia.
Our work also corroborated the previous clinical data 
reported by Killip and Kimball in 1967, as a higher LV filling 
pressure was synonymous of an in-hospital diagnosis of HF21. 
Similarly to recently published data on the Forrester invasive 
classification, PCWP was not an independent predictor of in-
hospital outcome8, as LVEDP was not in our study. This lack of 
prognostic influence could have the following explanations: 
first, although the present cohort represented a consecutive 
group of patients, not all patients submitted to a coronary 
angiogram were submitted to an invasive assessment of LV 
diastolic function. The in-hospital mortality for the 111 patients 
submitted to a coronary angiogram and whose diastolic 
function was not assessed was 9%, and therefore an exclusion 
of the highest risk patients might have occurred. Second, 
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Table 7 - Univariate predictors of readmission for congestive heart failure one year after the ACS
No event Event OR (95% CI) p
Number 596 22
Female gender* 151/596 (25.3) 6/22 (27.3) 1.11 (0.43 – 2.88) 0.84
STEMI* 243/578 (42.0) 14/21 (66.7) 2.76 (1.10 – 6.93) 0.03
Diabetes* 146/596 (24.5) 7/22 (31.8) 1.10 (0.83 – 1.48) 0.44
Hypertension* 392/560 (70.0) 16/20 (80.0) 1.71 (0.57 – 5.20) 0.34
TIMI risk score ≤ 2* 311/596 (52.2) 3/22 (13.6) 0.15 (0.04 – 0.49) <0.01
LVEDP ≥ 26.5mmHg * 190/596 (31.9) 14/22 (63.6) 3.74 (1.54 – 9.07) 0.02
Atrial fibrillation * 27/596 (4.5) 3/22 (13.6) 3.33 (0.93 – 11.94) 0.05
Normal coronary angiogram* 85/596 (14.3) 1/22 (4.5) 0.29 (0.04 – 2.16) 0.20
Incomplete percutaneous revascularization* 259/511 (50.7) 14/22 (66.7) 1.95 (0.77 – 4.90) 0.15
Diuretics 24 hours * 107/596 (18.0) 10/22 (45.5) 3.81 (1.60 – 9.04) 0.01
LVEDP (mmHg) º 22.8 ± 8.2 30.8 ± 8.6 <0.01
Peak troponin I (U/l) º 35.0 ± 53.3 88.5 ± 104.6 <0.01
Age (years) º 62.9 ± 12.1 74.2 ± 7.1 <0.01
LVEF (%) º 53.2 ± 9.9 41.1 ± 10.0 <0.01
BMI (kg/m2)º 27.7 ± 4.8 28.0 ± 3.0 0.77
º mean ± SD; * %
Multivariate Cox regression analysis for readmission due to congestive heart failure one year after the ACS
Variables HR p value 95% C I
LVEDP 1.10 <0.01 1.04 – 1.16
Age 1.10 0.01 1.02 – 1.16
Peak troponin I 1.01 0.03 1.00 – 1.01
Diuretics 24 hours 1.44 0.49 0.52 – 3.94
LVEF 0.98 0.31 0.95 – 1.02
Atrial fibrillation 0.94 0.95 0.12 – 7.38
STEMI 0.73 0.63 0.21 – 2.57
TIMI risk score ≤ 2 0.27 0.09 0.06 – 1.27
Number of events - 17; Population - 489; Chi square - 52.1 ; p < 0.01. LVEF - left ventricular ejection fraction; LVEDP - left ventricular-end diastolic pressure.
medical treatment with nitrates, diuretics and vasodilators 
influenced the loading conditions of the LV, and consequently 
LVEDP, and lastly, time evolution of the ACS might have had 
an impact on myocardial ischemia, development of fibrosis 
and changes in LV geometry, which also influenced filling 
pressures and LV distensibility22. 
 As previously described, early myocardial stunning may 
transiently increase LVEDP with subsequent normalization of 
filling pressures over the long term23. That associated with the 
exclusion of the 111 patients could also in our opinion explain 
the lower sensitivity and specificity of the proposed cutoff for 
LVEDP for the primary outcome of our analysis.
The importance of diastolic function as a marker of 
prognosis was in agreement with previous authors that 
analyzed the role of various echocardiographic markers, such 
as E/A ratio, the DT of the E wave, and the E/E’ ratio9-13. 
The E/E’ is the most reliable method of diastolic function 
assessment as correlation with LV filling pressures, and contrary 
to other indexes, it is present even in patients with preserved 
systolic function. When the E/E’ ratio exceedes 15, LV filling 
pressures are elevated and when the ratio is lower than 8, LV 
filling pressures are low24. An E/E’ ratio ranging from 8 to 15 
is considered suggestive, but not diagnostic, of diastolic LV 
dysfunction and other non-invasive investigations need to be 
performed to confirm the diagnosis of diastolic dysfunction4. 
Other disadvantages of the E/E´ ratio are due to the fact that 
tissue Doppler cannot separate active contraction from passive 
tethering, annular velocities vary depending on the location 
of the sample, and are influenced by “local” acute myocardial 
infarction and the presence of mitral annulus calcification12. 
Analyzing data from the work of Hill et al13, an E/E’ ratio 
greater than 15 had a prognostic significance, but the mean 
E/E’ ratio for the selected 250 patients post-AMI was 13.8 ± 
6.8, which was precisely in the “grey” zone area of the diastolic 
function assessment13. Nevertheless, the E/E’ ratio > 15 was 
an independent predictor of survival in the follow up. In our 
population, LVEDP also remained an independent predictor of 
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survival as a categorical variable (with a cutoff of 26.5 mmHg, 
data not shown), but lost that capacity as a continuous one. 
From diastolic to congestive HF
The higher prognostic value of invasive hemodynamic 
versus clinical signs of elevated filling pressures had already 
been described by Shell et al25. In our population we observed 
that the assessment of diastolic function had a higher predictive 
value for congestive HF readmission than clinical variables 
such as the Killip-Kimball class, and even the percutaneous 
revascularization grade.
The natural history of HF from an ischemic etiology is based 
on the development of diastolic dysfunction, followed by 
diastolic HF, and finally by the onset of systolic HF26. Pressure 
overload of the LV will cause myocyte stretching, increased 
wall stress, poorer subendocardial perfusion, and reduced 
energy production, which in turn will lead to neurohormonal 
activation and ventricular remodeling. These compensatory 
mechanisms are deleterious, and therefore will lead in the 
future to loss of LV systolic function and impaired survival. 
Our data strongly support this paradigm, as diastolic 
function was a determinant of congestive HF future admission, 
and therefore of LV remodeling namely in the group of patients 
with preserved systolic function. In the population with LVEF 
under 40% during the index ACS, diastolic function was not 
powerful enough to determine prognosis - systolic dysfunction 
overcame diastolic dysfunction. 
This subset of ACS patients with preserved ejection fraction 
and higher LVEDP should therefore not be stereotyped as low-
risk, and neurohormonal blocking, vasodilators and probably 
diuretics could have a crucial importance.
Study limitations
Although the present cohort represented a consecutive group 
of patients, not all patients submitted to a coronary angiogram 
had an invasive assessment of LV diastolic function as this was 
performed at the discretion of the invasive cardiologist. Moreover, 
only 60% of the 1,329 patients admitted to our coronary care unit 
were submitted to an invasive strategy. Therefore an exclusion 
of the highest risk patients might have occurred. We also regret 
our lost-to-follow-up rate of 5.4%.
Either systolic or diastolic indexes reflected instantaneous 
measurements, and could vary across the ACS period. Therefore 
a single measurement might not reflect the best prognostic index. 
Furthermore, there were no reports on the diastolic function 
previous to the index ACS admission, nor there was a noninvasive 
echocardiographic assessment of the mitral inflow.
Conclusions
In our ACS population, LVEDP was an independent predictor 
of a future HF readmission.
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